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Objective:  To  determine  whether  a clinically-utilised  IL-1  receptor  antagonist,  anakinra,  reduces  renal
inﬂammation,  structural  damage  and  blood  pressure  (BP)  in  mice  with  established  hypertension.
Methods:  Hypertension  was  induced  in male mice  by uninephrectomy,  deoxycorticosterone  acetate
(2.4  mg/d,  s.c.)  and  replacement  of  drinking  water  with  saline  (1K/DOCA/salt).  Control  mice  received
uninephrectomy,  a placebo  pellet  and  normal  drinking  water.  10  days  post-surgery,  mice  commenced
treatment  with  anakinra  (75 mg/kg/d,  i.p.)  or vehicle  (0.9%  saline,  i.p.)  for 11 days.  Systolic  BP  was
measured  by tail  cuff  while  qPCR,  immunohistochemistry  and  ﬂow  cytometry  were  used  to  measure
inﬂammatory  markers,  collagen  and immune  cell  inﬁltration  in  the  kidneys.
Results: By  10 days  post-surgery,  1K/DOCA/salt-treated  mice  displayed  elevated  systolic  BP
(148.3  ±  2.4 mmHg)  compared  to control  mice  (121.7  ±  2.7 mmHg;  n = 18,  P < 0.0001).  The  intervention
with  anakinra  reduced  BP  in  1K/DOCA/salt-treated  mice  by ∼20 mmHg  (n  = 16, P < 0.05),  but  had  no
effect  in controls.  In 1K/DOCA/salt-treated  mice,  anakinra  modestly  reduced  (∼30%) renal  expression
of  some  (CCL5,  CCL2;  n = 7–8; P  < 0.05)  but  not  all  (ICAM-1,  IL-6)  inﬂammatory  markers,  and  had  no  effect
on  immune  cell  inﬁltration  (n  =  7–8,  P  > 0.05).  Anakinra  reduced  renal  collagen  content  (n = 6,  P  <  0.01)
but  paradoxically  appeared  to  exacerbate  the  renal  and  glomerular  hypertrophy  (n = 8-9,  P <  0.001)  that
accompanied  1K/DOCA/salt-induced  hypertension.
Conclusion:  Despite  its anti-hypertensive  and  renal  anti-ﬁbrotic  actions,  anakinra  had  minimal  effects  on
inﬂammation  and  leukocyte  inﬁltration  in mice  with 1K/DOCA/salt-induced  hypertension.  Future  studies
will  assess  whether  the anti-hypertensive  actions  of  anakinra  are  mediated  by protective  actions  in  other
BP-regulating  or salt-handling  organs  such  as the  arteries,  skin  and  brain.
©  2016  The  Authors.  Published  by  Elsevier  Ltd. This  is an  open  access  article  under  the CC  BY-NC-ND
license  (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Abbreviations: ASC, apoptosis-associated speck-like protein containing a (CARD); BP, blood pressure; CARD, caspase activation and recruitment domain; CCL2, chemokine
ligand 2; CCL5, chemokine ligand 5; cDNA, complementary DNA; DAMP, danger-associated molecular pattern; DOCA, deoxycorticosterone acetate; GAPDH, glyceraldehyde
3-phosphate dehydrogenase; HRP, horseradish peroxidase; HSP, heat shock protein; ICAM-1, intercellular adhesion molecule 1; IL-18, interleukin 18; IL-18R, interleukin
18  receptor; IL-18RAcP, interleukin 18 receptor accessory protein; IL-1R, interleukin 1 receptor; IL-1RA, interleukin 1 receptor antagonist; IL-1, interleukin 1; IL-6,
interleukin 6; mmHg, millimetres of mercury; MW,  molecular weight; NF-B, nuclearfactor kappa-light-chain-enhancer of activated B cells; NLR, nod-like receptor; NLRC,
nod-like receptor with caspase-recruitment domain; NLRP, nod-like receptor with pyrin domain; NLRP3, nod-like receptor with pyrin domain containing 3; PAMP, pathogen-
associated molecular pattern; PBS, phosphate-buffered saline; PCR, polymerase chain reaction; PRR, pattern recognition receptor; RNA, ribonucleic acid; SPF, speciﬁc pathogen
free;  TLR, toll-like receptor; VCAM-1, vascular cell adhesion molecule 1.
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1. Introduction
Hypertension is now recognised as a low-grade inﬂammatory
condition with growing evidence to suggest that the cytokine, IL-
1, plays an important role. Previous studies have shown that
hypertensive patients have increased circulating levels of IL-1,
and furthermore that levels of IL-1 are positively correlated with
increasing blood pressure (BP) [1,2]. In a prospective study, it
was found that levels of IL-1 were signiﬁcantly higher in those
normotensive individuals who went on to develop hypertension
during the 6.5 year follow up [2]. This latter ﬁnding showing that
augmented levels of IL-1 precede rises in chronic BP is suggestive
of a causal role for the cytokine in the pathogenesis of hypertension.
Indeed, a causative role for IL-1 is also supported by recent
preclinical ﬁndings. IL-1 is formed from its inactive precursor, pro-
IL-1, by the actions of a class of innate signalling complexes known
as inﬂammasomes [3]. Inﬂammasomes are multimeric protein
complexes comprising of one of four pattern recognition receptors
(PRR) (NLRP1, NLRP3, AIM2, NLRC4) responsible for the detection
of pathogen- or danger-associated molecular patterns (PAMPs or
DAMPs) [3]; an adaptor protein, ASC; and pro-caspase-1, which is
ultimately responsible for cleaving pro-IL-1 into its active form.
Studies by our group and others have shown that various forms
of hypertension in mice are associated with increased expression
of inﬂammasome subunits and IL-1 in the kidneys. Moreover,
genetic deﬁciency of ASC or NLRP3, or treatment with an IL-1
neutralising antibody, afforded mice protection from hypertension,
renal inﬂammation and ﬁbrosis [4,5]. Collectively, the above ﬁnd-
ings highlight the inﬂammasome/IL-1 signalling pathway as a
potential target for new therapies to treat hypertension.
Anakinra is a recombinant form of the endogenous human
interleukin-1 receptor antagonist (IL-1Ra) that prevents IL-1 sig-
nalling by competitively binding to the IL-1 receptor (IL-1R) [6].
Anakinra is approved clinically for the treatment of chronic inﬂam-
matory diseases such as rheumatoid arthritis and neonatal-onset
multisystem inﬂammatory disease. However, whether anakinra
can also be used as a treatment for hypertension has not been
examined. Therefore, in the present study we evaluated the
effects of an intervention with anakinra on BP and markers of
renal inﬂammation and damage in one kidney/deoxycorticosterone
acetate/salt-dependent hypertension in mice.
2. Methods
2.1. Animals
178 male C57BL/6J mice, of age 10–12 weeks and weighing
25–30 g, were used in this study. Mice were obtained from the
Monash Animal Research Platform (MARP; Monash University,
Australia) or the Animal Resources Centre (Perth, Australia). Mice
were housed under speciﬁc pathogen free conditions, on a 12 h
light-dark cycle and provided with ad libitum access to normal chow
and drinking water. All procedures were conducted according to
the Australian Code for the Care and Use of Animals for Scientiﬁc
Purposes (8th edition) and were approved by the MARP Animal
Ethics Committee (Project number: MARP/2013/043).
2.2. Induction of hypertension
Mice were placed under general anaesthesia by isoﬂurane
inhalation (2.2–2.6% isoﬂurane in 100% O2). While under anaesthe-
sia, mice were monitored for hind-paw withdrawal, blink reﬂexes
and respiratory rate. Hypertension was inducted by removal of the
left kidney, implantation of a deoxycorticosterone acetate (DOCA)
pellet (2.4 mg/d, 21 d; Innovative Research of America, USA) into a
small subcutaneous pouch in the left scapular region, and replace-
ment of the drinking water with 0.9% saline (1K/DOCA/salt) [7].
Normotensive mice were also uninephrectomised but received a
placebo pellet and were maintained on normal drinking water
(1K/placebo).
2.3. Anakinra intervention protocol
10 days after surgery to induce hypertension, some mice were
further treated with either a low dose of anakinra (25 mg/kg/d;
Amgen, USA), a higher dose of anakinra (75 mg/kg/d) [8] or vehicle
(0.9% saline, 100 l) for the remaining 11 days of the experiment via
daily intraperitoneal (i.p.) injections. A cohort of normotensive mice
was also treated with anakinra or vehicle from 10 to 21 days post-
surgery. These doses of anakinra were chosen as they fall within the
range of doses that have previously been shown to be efﬁcacious
in other models of disease in mice [9,10]. Importantly, we saw no
signs of any adverse side-effects with these doses of anakinra (e.g.
weight loss, general appearance and behaviour, mortality rate, etc.).
2.4. Blood pressure measurements
Systolic BP was  measured via tail cuff plethysmography using a
multi-channel BP analysis system (MC4000; Hatteras Instruments,
USA). BP was  recorded for 30–40 measurement cycles daily for at
least 3 days prior to surgery to acclimatise mice to the procedure.
BP was  then measured just prior to surgery (day 0) and again on
days 3, 7, 10, 14, 17, and 21.
2.5. Renal messenger RNA (mRNA) expression of inﬂammatory
markers
Twenty-one days after surgery, mice were killed by isoﬂurane
overdose (Baxter Healthcare, Australia) and perfused through the
left ventricle with 0.2% clexane (400 IU, Sanoﬁ Aventis, Australia) in
RNAse-free phosphate-buffered saline (PBS). The right kidney was
excised and cut transversely with a scalpel blade. Half of the kidney
was set aside for immunohistochemistry or ﬂow cytometry, while
the other half was further divided into two  equal portions, each of
which were placed in a microcentrifuge tube and snap frozen in
liquid nitrogen. RNA was extracted from the same portion of these
frozen samples using a commercially available RNA extraction kit
(RNeasy Mini Kit: Qiagen, USA). The concentration and purity of
the RNA was determined by measuring absorbance at 230, 260,
and 280 nm with a Nanodrop 1000 Spectrophotometer (Thermo
Scientiﬁc, USA). Samples were considered to be sufﬁciently free of
protein and phenol contamination and suitable for PCR analysis
when the 260/280 and 260/230 ratios were ≥2.
RNA was reverse transcribed to cDNA using a commercially
available kit (High Capacity cDNA Reverse Transcription Kit;
Applied Biosystems, USA). cDNA was  then used as a template
for real-time PCR to measure mRNA expression of NLRP3, ASC,
pro-caspase-1, pro-IL-1, pro-IL-18, IL-18R, IL-18RAcP, CCL5, CCL2,
ICAM-1, VCAM-1, IL-6, collagen type 1 alpha 1 (COL1A1), collagen
type 3 alpha 1 (COL3A1), collagen type 4 alpha 1 (COL4A1), collagen
type 5 alpha 1 (COL5A1) and the house keeping gene, GAPDH (Taq-
man  Gene Expression Assays, Applied Biosystems, USA). Real-time
PCR was  then performed using a CFX96 Real-Time PCR Detection
System (Bio-Rad Laboratories, Australia) and the following thermo-
cycling parameters; an initial step of 50 ◦C for 2 min; 10 min  at
95 ◦C; 40 cycles of 95 ◦C for 15 s followed by 60 ◦C for 1 min. Flu-
orescence was measured at the end of each cycle. Fold-changes in
mRNA expression relative to the 1K/placebo + saline samples were
determined using the comparative CT method [11].
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2.6. Flow cytometric analysis of leukocyte inﬁltration into the
kidney
Single cell suspensions were prepared from half kidney sam-
ples. Brieﬂy, kidneys were minced with scissors and digested by
incubation for 30 mins at 37 ◦C in PBS containing collagenase type
XI (125 U/ml), collagenase type I-S (460 U/ml) and hyaluronidase
(60 U/ml) (Sigma-Aldrich, USA). Samples were passed through a
70 m ﬁlter before being subjected to a PercollTM gradient spin.
The layer containing mononuclear cells was transferred to a fresh
tube and stained with an antibody cocktail consisting of anti-mouse
CD45 (APC-Cy7; BioLegend, USA), CD11b (PacB, eBioscience, USA),
Ly6G (PE-Cy7; BioLegend, USA), CD3 (V500; BD Bioscience, USA),
CD4 (FITC; eBioscience, USA), CD8 (BV605; BioLegend, USA), F4/80
(APC; eBioscience, USA), and CD206 (PE; BioLegend, USA) diluted
in PBS containing 0.5% bovine serum albumin. Samples were then
analysed by ﬂow cytometry using a BD LSR FortessaTM (BD Bio-
science, USA) and FlowJo Software (version 10.1, Tree Star Inc, USA).
Cell numbers were normalised using CountBright counting beads
(Invitrogen, USA) and expressed as total cells per kidney.
2.7. Picrosirius red staining for the detection of renal interstitial
collagen and glomerular cross sectional area (GSA)
Kidney halves (composed of the renal cortex and medulla) were
ﬁxed in 10% formalin, embedded in parafﬁn and sectioned (5 m).
Sections were then deparafﬁnised, rehydrated and stained with
a 0.1% Picrosirius red solution. Imaging was performed using a
bright-ﬁeld microscope at ×20 magniﬁcation. To determine col-
lagen content, the percentage of area stained by Picrosirius red in
six randomly selected ﬁelds-of-view was quantiﬁed by a blinded
investigator using ImageJ software (National Institutes of Health,
USA). To determine glomerular cross sectional area (GSA), the
glomerular area was traced and analysed by inbuilt computerised
morphometry (DP-21), based on pixel size and magniﬁcation. For
the purpose of analysis, glomeruli were deﬁned as the matrix, cells,
and space within the circumference of the Bowman’s capsule.
2.8. Multiplex immunoassay for quantiﬁcation of antibody levels
in plasma
Blood was collected from the inferior vena cava in ethylene-
diaminetetraacetic acid (EDTA)-coated tubes and centrifuged to
separate plasma. The concentration of antibody isotypes (IgG1,
IgG2a, IgG2b, and IgG3) in plasma was quantiﬁed using a Pro-
cartaPlex Mouse Antibody Isotyping Panel (eBioscience, USA). The
antibody assay was run on a Bio-Plex
®
MAGPIX
®
Multi-Plex Reader
(BioRad, USA). Data were analysed using Procartaplex Analyst
(eBioscience, USA).
2.9. Enzyme-linked immunosorbent assay (ELISA) for detection of
IL-18 in plasma
An ELISA was performed to determine levels of active IL-18
released into the circulation of 1K/DOCA/salt-treated mice (Medical
Biological Laboratories, Japan). The assay was performed accord-
ing to manufacturer’s instructions in microtiter plates coated with
antibodies speciﬁc for IL-18. The amount of IL-18 in plasma sam-
ples was estimated by calibrating the optical density (OD) values
of the samples with the OD values of serially diluted recombinant
protein standard.
2.10. Statistical analysis
Data are expressed as mean ± SEM. Systolic BP was analysed
by two-way repeated measures ANOVA followed by Bonferroni
post-hoc test. All other data were analysed using either Student’s
unpaired t-test or two-way ANOVA followed by Newman-Keuls
post hoc test. P < 0.05 was  considered to be statistically signiﬁcant.
Note: post hoc tests were only performed where the f-ratio of the
ANOVA highlighted a signiﬁcant difference (P < 0.05). Data were
graphed and analysed using GraphPad Prism Software v6.04
3. Results
3.1. Anakinra reduces systolic BP in 1K/DOCA/salt-induced
hypertension
1K/DOCA/salt treatment in mice caused an increase in systolic
BP that appeared to plateau after 10 d to a level that was approx-
imately 30 mmHg  higher than baseline BP (Fig. 1A). Subsequent
treatment of hypertensive mice with either the vehicle for anakinra
(saline) or with a low dose of the drug (25 mg/kg/d) for the remain-
ing 11 d of the experiment had no apparent effect on BP (Fig. 1A).
By contrast, the higher dose of anakinra (75 mg/kg/d) reduced BP
by ∼15–20 mmHg  within 4 d and this effect was largely maintained
until the end of the treatment period (Fig. 1A). BP in control mice
that underwent 1K/placebo treatment did not deviate from base-
line over the ﬁrst 7–10 d. Moreover, treatment of 1K/placebo mice
with either vehicle, low dose anakinra or high dose anakinra, had
no further effect on BP (Fig. 1B). These observations suggest that
the high dose of anakinra (75 mg/kg/d) is effective at selectively
reducing BP in hypertensive but not normotensive mice. Thus, in
all subsequent experiments, the effects of only this higher dose of
anakinra were evaluated.
3.2. Anakinra reduces renal interstitial collagen deposition in
1K/DOCA/salt-treated mice
Hypertension is associated with renal interstitial ﬁbrosis [12].
Therefore, we determined whether the anti-hypertensive effect of
anakinra was  accompanied by a reduction in renal collagen levels.
Picrosirius red staining revealed approximately 8-fold higher levels
of interstitial collagen in kidneys of mice that were made hyperten-
sive by 1K/DOCA/salt and subsequently treated with vehicle, than
in normotensive mice treated with vehicle (Fig. 2A and B). Consis-
tent with its effects on BP, anakinra inhibited collagen deposition
in the kidneys of 1K/DOCA/salt-treated mice, but had no effect in
the normotensive animals (Fig. 2A and B).
To determine whether the effects of anakinra on collagen depo-
sition in hypertensive 1K/DOCA/salt-treated mice were mediated
at a transcriptional level, we  measured mRNA expression of four of
the major collagen subtypes, collagen I, III, IV, and V. The expression
of each of these collagen subtypes was markedly enhanced in kid-
neys from 1K/DOCA/salt-treated mice compared to normotensive
1K/placebo-treated animals (Fig. 2C–F). However, unlike its effects
on protein levels of interstitial collagen, anakinra did not reduce
mRNA levels of any collagen subtypes in either 1K/DOCA/salt- or
1K/placebo-treated mice (Fig. 2C–F).
3.3. Effect of anakinra on markers of renal inﬂammation and
damage
Collagen deposition often occurs in response to inﬂammation
and injury and thus we measured the effects of 1K/DOCA/salt and
anakinra treatments on markers of renal inﬂammation and injury
in mice. As per our previous report [4], 1K/DOCA/salt-induced
hypertension in mice was  associated with elevated renal expres-
sion levels of inﬂammasome subunits including NLRP3, ASC, and
pro-caspase-1 (Fig. 3A–C). Also consistent with our previous ﬁnd-
ing, mRNA expression of pro-IL-1 was elevated in the kidneys of
1K/DOCA/salt-treated mice (Fig. 3D). Intervention with anakinra
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Fig. 1. Effect of anakinra on systolic BP in 1K/DOCA/salt (A) and 1K/placebo-treated (B) mice. Blood pressure was  measured via tail-cuff plethysmography. 10 days after
surgery, mice were further treated with anakinra (75 or 25 mg/kg/d, i.p.) or vehicle (0.9% saline). Data are expressed as mean ± SEM (n = 10–18 per group). ****P < 0.0001 for
two-way repeated measures ANOVA; #P < 0.05, ###P < 0.001 for Bonferroni multiple comparisons test.
had no effect on expression levels of any of the above inﬂamma-
some subunits/cytokines in either 1K/DOCA/salt-treated mice or in
normotensive 1K/placebo mice (Fig. 3) suggesting that the drug is
likely to be acting downstream of inﬂammasome priming.
Real-time PCR also revealed that several markers of inﬂam-
mation and injury previously shown to lie downstream of
inﬂammasome activity/IL-1 were upregulated in the kidneys of
hypertensive 1K/DOCA/salt-treated mice relative to normotensive
1K/placebo-treated mice including the chemokines CCL5 and CCL2
(Fig. 4A–B); adhesion molecules ICAM-1 and VCAM-1 (Fig. 4C–D);
and the pro-inﬂammatory cytokine IL-6 (Fig. 4E). Anakinra atten-
uated 1K/DOCA/salt-induced increases in expression of CCL5 and
CCL2 by 25–40% (Fig. 4A–B) and appeared to have a similar
inhibitory impact on VCAM-1 expression. However, for this lat-
ter observation, the effect failed to reach statistical signiﬁcance
(Fig. 4D). Anakinra intervention also had little to no effect on ICAM-
1 or IL-6 expression in the kidneys of 1K/DOCA/salt-treated mice
nor did it reduce expression levels of any of the above inﬂammatory
markers in normotensive mice (Fig. 4A–E).
Chemokines play a crucial role in leukocyte trafﬁcking into the
kidneys and vascular wall during hypertension [7,13,14]. Thus,
given that anakinra reduced renal expression of CCL5 and CCL2 in
1K/DOCA/salt-treated mice, we performed ﬂow cytometric analy-
sis to determine if the drug similarly reduced leukocyte numbers in
the kidneys. Relative to normotensive mice, 1K/DOCA/salt-induced
hypertension was associated with elevated numbers of total leuko-
cytes in the kidneys (Fig. 5A). Further analysis of the immune
cell subsets that contributed to this revealed expansions in the
populations of CD4+ T cells, CD8+ T cells and CD206+ (“M2”)
macrophages, but no changes in CD206- (“M1”) macrophages or
neutrophils (Fig. 5B–F). For each of these cell types, and irrespective
of whether the mice were hypertensive (1K/DOCA/salt) or nor-
motensive (1K/placebo), anakinra had no effect on cell number
(Fig. 5A–F).
3.4. Effect of anakinra on renal hypertrophy
A previous report suggested that chronic treatment of rats with
anakinra was  associated with hypertrophy of the kidneys [15]. In
the present study we showed that while 11 d of anakinra treatment
had no effect on the kidney weight (normalised to body weight)
in the normotensive animals, it exacerbated renal hypertrophy
in 1K/DOCA/salt-hypertensive animals (Fig. 6A). These effects of
anakinra were also reﬂected at the glomerular level with anakinra
causing an increase in the average size of glomeruli within the
kidneys of 1K/DOCA/salt-treated mice (Fig. 6B).
4. Discussion
The major ﬁnding from this study is that the clinically-used
recombinant human IL-1Ra, anakinra, was  effective at reversing BP
and reducing renal ﬁbrosis in mice with established 1K/DOCA/salt-
dependent hypertension. This effect of anakinra occurred despite
the drug appearing to have only modest effects on renal inﬂamma-
tion and even exacerbating renal hypertrophy.
Previous studies using a variety of experimental models
(1K/DOCA/salt, angiotensin II infusion, renal artery clipping) have
demonstrated that inhibition of inﬂammasome activation or neu-
tralisation of IL-1 prior to the induction of hypertension is
effective at preventing subsequent increases in BP [4,5]. In the
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Fig. 2. Effect of anakinra on collagen in the kidneys of 1K/DOCA/salt and 1K/placebo treated animals. (A) Representative image (×20 magniﬁcation) and (B) quantiﬁed group
data  of Picrosirius red stained kidney sections. mRNA expression of (C) collagen type 1 alpha 1, (D) collagen type 3 alpha 1, (E) collagen type 4 alpha 1, and (F) collagen type
5  alpha 1. Data are expressed as mean ± SEM (n = 6-8 per group). **P < 0.01, ****P < 0.0001 for two-way ANOVA followed by Newman-Keuls multiple comparisons test.
present study we demonstrated that an intervention to inhibit IL-
1 signalling, initiated after 1K/DOCA/salt-dependent hypertension
had become established (i.e.  10 days post-surgery), caused a rapid,
albeit partial reversal of BP. Indeed, the magnitude of the effect
(15–20 mmHg) is signiﬁcant when one considers that in hyperten-
sive humans, every 10 mmHg  reduction in systolic BP equates to
a >20% reduction in risk of coronary heart disease and a >40% reduc-
tion in risk of stroke [16]. Importantly the treatment protocol used
herein more closely resembles how the condition is managed in the
clinic (i.e. treatment is only initiated once hypertension is estab-
lished and diagnosed). Hence, our ﬁndings lend further support to
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Fig. 3. Effect of anakinra on renal expression of inﬂammasome subunits; NLRP3 (A), ASC (B), pro-caspase-1 (C) and derived cytokine pro-IL-1 (D). Messenger RNA expression
was  measured with real-time PCR and quantiﬁed using the comparative CT method with GAPDH used as the housekeeping gene. Data expressed as mean ± SEM (n = 7–9 per
group) *P < 0.05, **P < 0.01, ***P < 0.001 for two-way ANOVA followed by Newman-Keuls multiple comparisons test.
the concept that the inﬂammasome/IL-1 signalling pathway is a
promising target for novel anti-hypertensive therapies.
Previous studies highlight the kidneys as a major site of inﬂam-
masome activation and suggest that this is an important driver of
renal inﬂammation, which in turn leads to interstitial ﬁbrosis and
renal dysfunction [4,5,12]. Inﬂammation and ﬁbrosis in the kidneys
are thought to disrupt the pressure-natriuresis relationship, lead-
ing to Na+/H2O retention and increased arterial BP [12,17–20], thus
providing an explanation of how inﬂammasome activation may
contribute to hypertension. Indeed, in the present study we  pro-
vided evidence for inﬂammasome priming as well as upregulation
of IL-6 which is purported to be regulated downstream of IL-1R1
signalling [21,22] and several other markers of inﬂammation in the
kidneys of 1K/DOCA/salt-treated mice. These ﬁndings are consis-
tent with our previous report where, in addition to demonstrating
increased mRNA expression of inﬂammasome subunits, pro-IL-
1 and IL-6, we provided evidence for inﬂammasome/caspase-1
activation and protection against 1K/DOCA/salt-dependent hyper-
tension and renal inﬂammation in ASC−/− mice [4]. However, in
the present study anakinra had little to no effect on measures of
renal inﬂammation, despite its robust anti-hypertensive actions.
A potential explanation for the differential effect of anakinra and
ASC-deﬁciency on renal inﬂammation is that the former inter-
vention will only target IL-1R1 signalling, whereas the latter is
likely to inhibit both IL-1 and IL-18-dependent pathways [3].
This may  indicate that the IL-18 system is more important than
IL-1 for promoting renal inﬂammation, at least in the context
of 1K/DOCA/salt-dependent hypertension. Although we have not
yet tested for a possible anti-inﬂammatory effect in the kidneys
of selective inhibition of IL-18 signalling, we do have preliminary
evidence to suggest that this arm of the IL-1 family is upregu-
lated in 1K/DOCA/salt-dependent hypertension. Speciﬁcally, we
have shown that although renal mRNA and circulating levels of IL-
18 itself remain unchanged, expression of both the IL-18 receptor
(IL-18R) and the IL-18R accessory protein (IL-18RAcP) are markedly
upregulated in the kidneys of mice with 1K/DOCA/salt-dependent
hypertension (Supplementary Fig. S1).
The previous discussion implies that the BP-lowering effects of
anakinra occurred independently of any anti-inﬂammatory actions
in the kidneys. By extension, this suggests that the site of action
of anakinra is possibly another BP-regulating organ/tissue. Previ-
ous studies have established the important association between
vascular inﬂammation, endothelial dysfunction and hypertension,
suggesting that the blood vessels may  be one such site. For exam-
ple, experimentally-induced hypertension in mice is associated
with increased expression of inﬂammatory cytokines in the arterial
wall, including IL-1 and IL-6, which is accompanied by inﬁl-
tration and activation of leukocytes such as T cells, B cells and
macrophages [7,23,24]. Inhibition of these inﬂammatory factors
and/or cells using neutralising antibodies, chemokine receptor
antagonists or knockout mouse models reduces endothelial dys-
function and BP in hypertensive animals [7,23,24]. While the
mechanisms linking inﬂammation to impaired vasorelaxation in
these models have not been fully elucidated, there is some evidence
that IL-1 could directly inﬂuence these parameters. For example,
three independent studies showed that large and resistance-like
arteries from rats displayed impaired endothelium-dependent
relaxations to (acetylcholine) ACh and augmented contractions
to phenylephrine following exposure to IL-1 ex vivo [25–27].
Furthermore, IL-1-treated vessels generated more superoxide
than controls and treatment of the vessels with superoxide dis-
mutase partially reversed the impaired responses to ACh [26]
implicating a role for oxidative stress. Based on these previous
observations, in pilot studies we  investigated the effects of the
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Fig. 4. Effect of anakinra on renal expression of chemokines CCL5 (A) and CCL2 (B); adhesion molecules ICAM-1 (C) and VCAM-1 (D) and the pro-inﬂammatory cytokine
IL-6  (E). Messenger RNA expression was measured with real-time PCR and quantiﬁed using the comparative CT method with GAPDH used as the housekeeping gene. Data
expressed as mean ± SEM (n = 7–9 per group) *P < 0.05, ****P < 0.0001 for two-way ANOVA followed by Newman-Keuls multiple comparisons test.
1K/DOCA/salt- and anakinra- treatments on endothelial function
in second order mesenteric resistance-like arteries (Supplementary
Fig. S3). Surprisingly, we neither saw any evidence of endothelial
dysfunction in the (saline-treated) 1K/DOCA/salt-treated mice, nor
did anakinra appear to augment endothelium-dependent vasore-
laxation responses in these animals. Hence, these ﬁndings suggest
that impaired vasodilator function has only a minor (if any) contri-
bution to chronic pressor effects to 1K/DOCA/salt and, by extension
that the BP-lowering actions of anakinra observed here were
unlikely to be due restoration/improvement of endothelial func-
tion.
Of course, it is also possible that anakinra did reduce renal
inﬂammation in the early stages of treatment. However, by the time
of assessment these anti-inﬂammatory effects had already waned.
In such a scenario, it is conceivable that there might be a time lag
between reversal of the anti-inﬂammatory action of anakinra com-
pared to that of downstream processes such as collagen deposition
and elevated BP, such that these latter parameters remained atten-
uated at the end of the 10-day anakinra treatment period. As to
potential reasons why the IL-1R-inhibiting effects of anakinra may
have been transient, it is worth noting that as a recombinant human
protein, anakinra has the potential to induce an immune response
when chronically administered to other species. Indeed, we  have
evidence that hypertensive mice administered with anakinra have
higher plasma IgG levels than those animals administered with
vehicle (Supplementary Fig. S2), and it is possible that such anti-
bodies could be acting to neutralise the effects of the protein.
Regardless, the previous discussion highlights an important lim-
itation of the current study (i.e. inﬂammation was only assessed
at one time-point) and indicates that further analysis of the time-
course and long-term actions of anakinra on renal inﬂammation,
ﬁbrosis and BP are warranted. Interestingly, the human monoclonal
anti-IL-1 antibody, Canikumab, is currently under investigation
for the prevention of recurring cardiovascular events. As this does
not involve cross-species protein administration, the problems
associated with generation of auto-antibodies to the treatment
encountered in the current study will not be applicable. Therefore,
it will be interesting to observe any reduction in blood pressure
with Canikumab treatment.
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Fig. 5. Effect of anakinra on leukocyte inﬁltration; Total leukocytes (A), T helper cells (B), cytotoxic T cells (C), “M1” macrophages (D), “M2” macrophages (E) and neutrophils (F)
in  the kidneys of 1K/DOCA/salt and 1K/placebo-treated mice. Leukocyte inﬁltration was  quantiﬁed by ﬂow cytometric analysis. Data are expressed as mean ± SEM (n = 11–17
per  group). *P < 0.05, ***P < 0.001, ****P < 0.0001 for two-way ANOVA followed by Newman-Keuls multiple comparisons test.
Finally, we observed that anakinra exacerbated renal hypertro-
phy in 1K/DOCA/salt-treated mice, a ﬁnding that is consistent with
an earlier study where it was reported that chronic treatment of rats
with a high dose of anakinra (200 mg/kg/d) for 6 months similarly
induced an increase in kidney weight [15]. While renal hyper-
trophy is often suggestive of renal injury [28], previous studies
demonstrating that anakinra limits renal damage and dysfunction
in several disease and injury settings including heatstroke in rab-
bits [29] and endotoxin- or antibody-mediated nephritis in rodents
[30,31], tends to argue against such an effect. Furthermore, our
observation that anakinra reduced picrosirius red staining in kid-
neys of hypertensive mice is also indicative of a protective rather
than detrimental action of the drug. Picrosirius red is established
to be a valid tool for the detection of collagen networks in tis-
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Fig. 6. Effect of anakinra on right kidney weight and glomerular surface area in
1K/placebo and 1K/DOCA/salt treated mice. Kidney weight was  normalised to ani-
mal  body weight (n = 7–9 per group). Glomerular surface area was determined using
analysis of Picrosirius red stained sections of the kidney. Data are expressed as
mean ± SEM (n = 7-9 per group). *P < 0.05, ***P < 0.001, ****P < 0.0001 for two-way
ANOVA followed by Newman-Keuls multiple comparisons test.
sues [32], and thus the reduction in picrosirius red staining in
kidneys from hypertensive mice treated with anakinra is consistent
with a protective effect against 1K/DOCA/salt-induced renal ﬁbro-
sis. Picrosirius red is not suitable, however, for discerning between
different subtypes of collagen [32]. Thus, to gain some insight into
which collagen subtypes were altered by anakinra treatment, and
the mechanisms involved, we measured expression levels of the
genes encoding four of the most common types of ﬁbrillar col-
lagens – I, III, IV and V – by real-time PCR. Although expression
levels of all of these genes were higher in the 1K/DOCA/salt- versus
1K/placebo-treated mice, none of them appeared to be affected by
further treatment with anakinra. There are at least two  potential
explanations for the apparent discrepancies between these obser-
vations and our ﬁnding of reduced picrosirius red staining. First,
it is plausible that the reduced amounts of interstitial collagen in
anakinra-treated animals was the result of enhanced breakdown,
rather than decreased production of the protein. Such a pro-
cess could result from upregulation of matrix metalloproteinases
(MMPs) [33], and hence in future studies it may  be worthwhile
measuring the impact of anakinra treatment on levels of MMPs
in the kidneys of 1K/DOCA/salt-treated mice. Alternatively, other
classes of collagen(s) may  have contributed to the renal interstitial
ﬁbrosis observed in this model e.g.  Type VI; [34], and it was these
classes that were most affected by anakinra treatment. Hence, fur-
ther characterisation of the extracellular matrix composition of the
kidneys via real-time PCR and/or immunostaining is warranted.
In conclusion, we  have demonstrated that anakinra – a drug
that is already used clinically in the treatment of autoimmune and
inﬂammatory diseases such as rheumatoid arthritis and gout –
is effective at reducing BP and renal collagen deposition in mice
with established hypertension. While questions remain around the
precise mechanisms involved in the anti-hypertensive actions of
anakinra, our results are further evidence of the immune basis of
hypertension and provide proof-of-concept that interventions tar-
geting immune dysregulation, hold promise as future therapies for
the condition.
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